RBR-65trt53Other1 期
Double-blind, randomized, placebo-controlled study to assessSafety and Effectiveness of Protection Against SARS-Cov-2 Infection: Infusion ofMesenchymal Stem Cells (MSCs) from expanded deciduous tooth pulps,As Allogeneic Therapeutic Strategy.
R-Crio Criogenia S.A.0 个研究点开始时间: 2020年12月14日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- Other
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 60Y 至 0（—）
入选标准
- •Man or woman; aged 60 years or over; with laboratory confirmation of the infection (COVID-19) by polymerase chain reaction with reverse transcription (RT-PCR); presence of at least one risk factor (co-morbidity) beyond age; adequate and healthy hematological values; hemoglobin 100 g / L, neutrophils 1.0 x 10 (9) / L, platelets 150 x 10 (9) / L; adequate livre function; ALT and AST 2.5 x ULN, bilirubin 1.5 x ULN;Adequate renal function; calculated creatinine clearance 50 mL / min; written informed consent signed by the candidate.
排除标准
- •Patients with severe allergies; serious basic illnesses that affect survival, including blood disorders, cachexia, active bleeding, severe malnutrition; obstructive pulmonary pneumonia, severe pulmonary interstitial fibrosis, alveolar proteinosis, allergic alveolitis and other known viral pneumonia or bacterial pneumonia; continuous use of immunosuppressive agents or organ transplants in the last 6 months; cancer being treated or even treated (a formal opinion from the responsible doctor is required); low adherence and unable to complete the full study; increased risk of the subject or other conditions that interfere with the clinical trial and the judgment of results such as excessive stress, sensitivity or cognitive impairment.
研究者
相似试验
进行中（未招募）
1 期
Efficacy, safety, and tolerability of Ancrod in patients with sudden hearing losssudden sensorineural hearing loss (SSHL)MedDRA version: 20.0Level: LLTClassification code 10040016Term: Sensorineural hearing lossSystem Organ Class: 100000013775EUCTR2012-000066-37-CZordmark Arzneimittel GmbH & Co. KG115
进行中（未招募）
1 期
Efficacy, safety, and tolerability of Ancrod in patients with sudden hearing losssudden sensorineural hearing loss (SSHL)MedDRA version: 20.0Level: LLTClassification code 10040016Term: Sensorineural hearing lossSystem Organ Class: 100000004854EUCTR2012-000066-37-DEordmark Arzneimittel GmbH & Co. KG115
招募中
3 期
Activity of Curcumin derivative on Joint Inflammation (knees) of the patients.CTRI/2023/09/058104Sam Sabinsa Group Limited
招募中
不适用
Double-blind, randomized, placebo controlled study to REduce STEroids in Relapsing Nephrotic syndromeNL-OMON47536Radboud Universitair Medisch Centrum80
已完成
不适用
Double-blind, placebo-controlled, randomized study to investigate the tolerability, safety, pharmacokinetics, and pharmacodynamics of ACT-541468: Part A: Multiple-ascending doses in healthy young adults after morning administration. Part B: Single-ascending doses in healthy elderly subjects after morning administration. Part C: Repeated doses in both healthy young adults and elderly subjects after evening administration.insomniaSleeping disorderssleeping disorderNL-OMON42430Actelion Pharmaceuticals84